Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

18 May 2017

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

The promising results from a clinical trial developed and run by investigators at Melanoma Institute Australia are being presented in Chicago at the world’s largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, attended by more than 30,000 delegates from around the world. 

The ground-breaking Anti-PD1 Brain Collaboration (ABC) clinical trial involved advanced melanoma patients being given a combination of two different immunotherapy drugs: nivolumab (Opdivo®) and ipilimumab (Yervoy®).

Results from an early analysis of this trial show 79% of advanced melanoma patients with brain metastases treated with the combination immunotherapy were still alive at six months. 66% of those who got nivolumab alone were also alive after six months.

Typically, patients with active brain metastases survive only four to five months and never even used to be admitted to clinical trials because their prognosis was so dire.

“This is an absolute game-changer for how we treat patients with advanced melanoma which has spread to the brain. It provides new hope to the 1,800 Australians expected to die from melanoma this year,” said Professor Georgina Long, the study’s chief investigator, Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.

“Quite simply, having brain metastases is no longer a death sentence,” she said. “We can now offer additional years of life and also the hope of ultimately beating this disease to a significant number of people.”

In February 2016, Australia approved the use of nivolumab for advanced melanoma patients as a stand-alone treatment or in combination with ipilimumab.

However, patients with brain metastases were excluded from previous clinical trials, including the ones that led to the drugs’ approval. This was what prompted Melanoma Institute Australia to develop and run the world-first ABC trial.

“I have melanoma patients with brain metastases who would not be alive today if they had not participated in this trial,” Professor Long said.

The study also examined patients who had no previous drug therapy prior to joining the trial, and those who received previous targeted drug therapy which is effective in patients with BRAF mutations in their melanoma.

It found that the combination of nivolumab and ipilimumab was more active in patients who had not received prior targeted BRAF-directed drug therapy.

Under the current Pharmaceutical Benefits Scheme (PBS) in Australia, doctors are restricted in the order in which they can prescribe the targeted BRAF-directed drug therapies and immunotherapy as treatments for melanoma. The restrictions make it very difficult to give immunotherapy first to patients who have the BRAF mutation in their melanoma (approximately 40% of all melanoma patients).

However, this new research strongly suggests that immunotherapy should be the first-line treatment in suitable patients, in particular, those with brain metastases.

Young dad, Leigh Miller (pictured here), is just one of the patients on the ABC Trial who has had a remarkable turnaround.

Evidence drives sweeping changes to melanoma treatment recommendations
25 May 2018

Evidence drives sweeping changes to melanoma treatment recommendations

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts. 

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
27 Apr 2018

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

The inspiring story of Emma Betts premieres on Australian Story
16 Apr 2018

The inspiring story of Emma Betts premieres on Australian Story

'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma. 

Toyota helps tackle Australia's national cancer - melanoma
09 Apr 2018

Toyota helps tackle Australia's national cancer - melanoma

Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.

Tackling the Kokoda Trail for melanoma
06 Apr 2018

Tackling the Kokoda Trail for melanoma

Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.

Professor Richard Scolyer presents at world's largest annual meeting of pathologists
29 Mar 2018

Professor Richard Scolyer presents at world's largest annual meeting of pathologists

Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.

Congratulations to Kaye Oakley
29 Mar 2018

Congratulations to Kaye Oakley

A round of applause for a well deserved win.

Farewell from Carole Renouf, CEO of Melanoma Institute Australia
26 Mar 2018

Farewell from Carole Renouf, CEO of Melanoma Institute Australia

A message from our CEO, Carole Renouf

Marching in the twilight
26 Mar 2018

Marching in the twilight

Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma. 

Researchers uncover treatment sequence for advanced melanoma patients
23 Mar 2018

Researchers uncover treatment sequence for advanced melanoma patients

Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.

An unsung hero of melanoma care for nearly 30 years
22 Mar 2018

An unsung hero of melanoma care for nearly 30 years

Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.

Sharing our research on melanoma surgery
21 Mar 2018

Sharing our research on melanoma surgery

MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.

14 Melanoma Marches down, 7 to go!
19 Mar 2018

14 Melanoma Marches down, 7 to go!

It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.

Melanoma March keeps marching
14 Mar 2018

Melanoma March keeps marching

Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.

Melanoma March kicks off for 2018
08 Mar 2018

Melanoma March kicks off for 2018

Melanoma Institute Australia's annual fundraising initiative is all systems go!

Calls for urgent crackdown on illegal backyard solariums
07 Mar 2018

Calls for urgent crackdown on illegal backyard solariums

The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
28 Feb 2018

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.